The protection provided by the world’s first malaria vaccine all but disappears after seven years, according to a new study. A phase-two clinical trial of Mosquirix (RTS,S) in Kenya showed just 4 percent effectiveness in children older than 7 years. With an already relatively low rate of malaria prevention, this is another setback for GlaxoSmithKline, the developer of the vaccine.
Then again, in Bill’s own words, a really effective vaccine will help lower the world’s population by 10 or 15 percent:
Gates: First, we’ve got population. The world today has 6.8 billion people. That’s headed up to about nine billion. Now, if we do a really great job on new vaccines, health care, reproductive health services, we could lower that by, perhaps, 10 or 15 percent, but there we see an increase of about 1.3.